By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:



Company News
Ignyta (RXDX) To Host Conference Call And Webcast Update On Entrectinib Program And STARTRK-2 On April 27, 2017 4/25/2017 7:26:19 AM
Ignyta (RXDX) Announces Peer-Reviewed Publication Of Activity Of A TRK Inhibitor In A Primary Brain Tumor: Successful Treatment Of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published In Precision Oncology 3/30/2017 6:14:32 AM
Ignyta (RXDX) Announces Exploration Of Strategic Options For Taladegib, Enabled By Amendment Of Taladegib License Agreement With Eli Lilly (LLY) 3/24/2017 6:35:26 AM
Ignyta (RXDX) Announces Full Year 2016 Company Highlights And Financial Results 3/15/2017 8:11:02 AM
Angsana's RNA-Based Fusions Cancer Panel Selected For Ignyta (RXDX)'s STARTRK2 Clinical Trial In Asia-Pacific 3/3/2017 7:17:55 AM
Ignyta (RXDX)'s Updated Phase 1 Data On Safety, Anti-Tumor Activity And CNS Activity Of Entrectinib In Cancers With TRK, ROS1 Or ALK Fusions Published In Cancer Discovery 2/9/2017 6:17:42 AM
Ignyta (RXDX) Release: Late-Breaking Oral Plenary Presentation Of A Novel Entrectinib Combination Regimen At The 2016 EORTC-NCI-AACR Annual Meeting 12/2/2016 11:01:32 AM
Ignyta (RXDX) Announces Compelling Phase I/Ib Clinical Data On RXDX-105, Its VEGFR-Sparing RET Inhibitor, At The 2016 EORTC-Ignyta (RXDX)-NCI Annual Meeting 12/1/2016 10:50:12 AM
Ignyta (RXDX) To Debut Preclinical Data On RXDX-106 At The 2016 EORTC-NCI-AACR Annual Meeting 11/29/2016 10:58:32 AM
Ignyta (RXDX) Announces EAP Designation And CE Marking For Its Trailblaze Pharos Clinical Trial Assay 11/15/2016 10:17:14 AM